| Imagery Source: iStock / Georgejason |
| Information Source: Illumina |
- Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis)
|
- GAAP operating margin of 15.8% and non-GAAP operating margin of 20.4% for Q1 2025
|
- GAAP diluted EPS of $0.82 and non-GAAP diluted EPS of $0.97 for Q1 2025
|
- Cash provided by operations of $240 million and free cash flow of $208 million for Q1 2025
|
- For fiscal year 2025, we expect:
|
-
- Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single-digit growth previously
|
-
-
- Revenue outside of the Greater China region is expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting changes in the research funding environment, as well as the projected benefit from pricing actions
|
-
-
- Reported revenue from the Greater China region is expected to be $165 - $185 million in 2025 (with $72 million in revenue recognised in Q1 2025)
|
-
- $85 million in tariff-related costs, which, after actions, is an approximate 125 bps reduction in fiscal year 2025 operating margin and $0.25 of EPS
|
-
- Non-GAAP operating margin of approximately 21.5% - 22.0%, down from approximately 23% previously; and non-GAAP diluted EPS in the range of $4.20 - $4.30, a reduction from our March guidance of approximately $4.50, primarily due to the net impact of tariffs
|
| Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2025. |
| "I'm proud that the Illumina team delivered strong Q1 revenue and EPS, a good start to the year in an increasingly dynamic business environment," said Jacob Thaysen, Chief Executive Officer. "Our outlook for the year has weakened due to shifting policy and geopolitical development, and we have taken swift incremental actions to protect our earnings. Our strategic focus remains on customer collaboration, driving differentiated innovations, and delivering on our long-term financial targets of growth and profitability." |
| Capital expenditures for free cash flow purposes were $32 million for Q1 2025. Cash flow provided by operations was $240 million, compared to $284 million in the prior year period. Free cash flow (cash flow provided by operations less capital expenditures) was $208 million for the quarter, compared to $251 million in the prior year period. Depreciation and amortisation expense was $69 million for Q1 2025. At the close of the quarter, the company held $1.24 billion in cash, cash equivalents and short-term investments. |
| Share repurchases for Q1 2025 were $200 million, and the company intends to repurchase incremental shares over the year as part of our ~$1.2 billion authorisation remaining at the end of the quarter. |
| Key announcements since our last earnings release |
- Instituted an incremental $100 million cost reduction program to mitigate the impact of a range of potential scenarios for a reduction in revenue and related operating income from the company's Greater China business
|
- Unveiled first-of-its-kind spatial transcriptomics technology; Broad Institute to collaborate on flagship project.
|
- Announced collaboration with Broad Clinical Labs to rapidly streamline and scale single-cell projects with cutting-edge tools and workflows
|
- Unveiled a series of roadmap innovations spanning genomics, spatial transcriptomics, single-cell analysis, CRISPR technologies, epigenetics, and data analytics software
|
- Sequenced 250,000 whole genomes for the Alliance for Genomic Discovery (AGD) initiative
|
- Announced partnership with Tempus to accelerate clinical adoption of next-generation sequencing tests through novel evidence generation
|
- Dr. Scott Gottlieb was elected as Board Chair, and Keith Meister joined the Board of Directors.
|
- Named for the sixth year in a row to the Dow Jones Best-in-Class World Index and the Dow Jones Best-in-Class North America Index
|
| A full list of recent announcements can be found in the company's NewsCenter. |
| Financial outlook and guidance
For fiscal year 2025, we expect: |
| · |
-
- Core Illumina revenue to decline between (1%) and (3%) on a constant currency basis year over year, down from low single-digit growth previously
|
-
-
- Revenue outside of the Greater China region is expected to grow between 0% and 2% in 2025 on a constant currency basis year over year and includes our estimate reflecting changes in the research funding environment, as well as the projected benefit from pricing actions
|
-
-
- Reported revenue from the Greater China region is expected to be $165 - $185 million in 2025 (with $72 million in revenue recognised in Q1 2025)
|
-
- $85 million in tariff-related costs, which, after actions, is an approximate 125 bps reduction in fiscal year 2025 operating margin and $0.25 of EPS
|
-
- Non-GAAP operating margin of approximately 21.5% - 22.0%, down from approximately 23% previously; and non-GAAP diluted EPS in the range of $4.20 - $4.30, a reduction from our March guidance of approximately $4.50, primarily due to the net impact of tariffs
|
| For the full document, click the link below |
| Illumina, Inc |
| Stay ahead of the curve! Subscribe to InsidEntity for daily updates on all your favourite companies. |
